Ligand Pharmaceuticals
LGND
416 hedge funds and large institutions have $7.15B invested in Ligand Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 98 funds opening new positions, 149 increasing their positions, 114 reducing their positions, and 35 closing their positions.
877% more call options, than puts
Call options by funds: $132M | Put options by funds: $13.5M
180% more first-time investments, than exits
New positions opened: 98 | Existing positions closed: 35
72% more capital invested
Capital invested by funds: $4.15B → $7.15B (+$2.99B)
50% more funds holding in top 10
Funds holding in top 10: 8 → 12 (+4)
31% more repeat investments, than reductions
Existing positions increased: 149 | Existing positions reduced: 114
16% more funds holding
Funds holding: 359 → 416 (+57)
8.54% more ownership
Funds ownership: 104.35% → 112.89% (+8.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$89.1M |
| 2 |
Neuberger Berman Group
New York
|
+$58.2M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$42.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$39.3M |
| 5 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$36.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$15M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$14.5M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$13.7M |
| 4 |
Goldman Sachs
New York
|
-$13.6M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$13.6M |
LGND Hedge Fund Activity: Q2 2026 in Review
416 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2026, worth a combined $7.15B — up 72% from $4.15B a quarter earlier.
Buyers outnumbered sellers: 98 funds opened new LGND positions and 35 closed out — a net gain of 63 holders — while 149 added to existing stakes and 114 trimmed.
The largest buyer was Invesco, adding an estimated $89.1M. The largest seller was Bank of Montreal, cutting an estimated $15M.
- 416 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2026, up from 359 in Q1 2026.
- Funds reported $7.15B of Ligand Pharmaceuticals stock for Q2 2026, up 72% quarter-over-quarter.
- 98 funds opened new Ligand Pharmaceuticals positions in Q2 2026 and 35 closed out, a net change of +63 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2026 was Invesco, an estimated $89.1M added.
- The largest Ligand Pharmaceuticals seller in Q2 2026 was Bank of Montreal, an estimated $15M sold.
Based on aggregated 13F filings for Q2 2026.